Latest News

EPR and CRP Predict Adverse Events in COPD Exacerbations


 

TOPLINE:

C-reactive protein (CRP) levels and eosinophil-to-platelet ratio (EPR) are significant independent predictors of adverse events in patients with chronic obstructive pulmonary disease (COPD) hospitalized with acute exacerbations.

METHODOLOGY:

  • Known risk factors for COPD exacerbations do not fully explain the variation in susceptibility among patients; data on potential biomarkers as predictors of COPD exacerbations are limited.
  • In a prospective, observational study at a single center, the researchers examined clinical and lab data including serum CRP levels, EPR, sarcopenia, lung function, nutrition, and frailty.
  • The study population included 200 adults older than 40 years with COPD who were hospitalized for acute exacerbations; 50 experienced adverse events.

TAKEAWAY:

  • Both elevated CRP and low EPR were significant predictors of adverse events in adjusted analysis in patients with COPD exacerbations (area under the curve, 0.71 and 0.76, respectively).
  • In a multivariate analysis, EPR and CRP, as well as sarcopenia, were significantly associated with adverse events (adjusted odds ratios, 2.33, 2.09, and 1.97, respectively).
  • COPD symptom scores, frailty, and malnutrition showed predictive value in bivariate but not multivariate analysis.

IN PRACTICE:

“Screening for these biomarkers [EPR and CRP] on admission could help identify high-risk patients who need more aggressive monitoring and treatment,” the researchers wrote in their discussion.

SOURCE:

The lead author on the study was Rohankumar Gandhi, MD, of Guru Gobind Singh Government Hospital, Jamnagar, India. The study was published online in Cureus.

LIMITATIONS:

The use of data from a single center, lack of information on nutritional interventions and counseling, and lack of data on outpatient outcomes limited the study findings.

DISCLOSURES:

The study received no outside funding. The researchers had no financial conflicts to disclose.

A version of this article appeared on Medscape.com.

Recommended Reading

Blood Eosinophil-Directed Prednisolone Proves Noninferior to Standard Care for COPD Exacerbations
MDedge Internal Medicine
Systemic Bias in AI Models May Undermine Diagnostic Accuracy
MDedge Internal Medicine
CPAP Oversells and Underperforms
MDedge Internal Medicine
Death Risk Takes Decades to Revert to Normal in Ex-Smokers
MDedge Internal Medicine
JAMA Internal Medicine Editor Recaps 2023’s High-Impact Research
MDedge Internal Medicine
High and Low Body Mass Indices Promote Respiratory Symptoms
MDedge Internal Medicine
Gabapentinoids Increase Exacerbation in COPD
MDedge Internal Medicine
Female Reproductive Factors Could Predict COPD Risk
MDedge Internal Medicine
Dupilumab Earns FDA Priority Review for Add-On COPD Care
MDedge Internal Medicine
Lung Cancer Screening Unveils Hidden Health Risks
MDedge Internal Medicine